Related Experiment Videos
Biomarkers of subclinical cholestasis predict cancer immunotherapy outcomes
Anne-Laure Mallard de La Varende1, Marine Fidelle1, Guido Kroemer2,3,4
1Gustave Roussy (GRCC), ClinicObiome, Inserm UMR1367, Microbiota and Mucosal Immunity for Cancer Immunotherapy, Université Paris-Saclay, Villejuif, France.
Oncoimmunology
|October 15, 2026
Abstract:
In a recent paper published in Cancer Cell, we identified subclinical cholestasis as an accessible imprint of gut dysbiosis predicting resistance to immune checkpoint blockade. Our work connects γ-glutamyl transferase, bile-acid remodeling, and MAdCAM-1 loss to compromised antitumor immunity, opening avenues for novel biomarker-guided microbiota interventions.